Skip to main content
Equibles
ALT logo

ALT · Altimmune, Inc. · Webcasts, Transcripts & Audio

Track ALT — free

Use ALT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.68 -0.06 (-2.01%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$575.77M
Shares
194.52M
Volume · Oct 5 3.84M Avg daily vol (3M) 4.15M

Altimmune, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Altimmune, Inc. (ALT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼98.7% $2,000 −$23.52M '22 Q3 22-11-10 ▼103.4% $ −$21.66M '22 Q4 23-02-28 ▼34.4% $21,000 −$20.07M '23 Q1 23-05-11 ▼25% $6,000 −$16.06M '23 Q2 23-08-10 ▲18000% $362,000 −$20.67M '23 Q3 23-11-07 · $37,000 −$31.64M '23 Q4 24-03-27 ▼76.2% $5,000 −$24.39M '24 Q1 24-05-09 ▼16.7% $5,000 −$24.64M '24 Q2 24-08-08 ▼98.6% $5,000 −$22.84M '24 Q3 24-11-12 ▼86.5% $5,000 −$23.18M '24 Q4 25-02-27 ▲0% $5,000 −$19.57M '25 Q1 25-05-13 ▲0% $5,000 −$22.15M '25 Q2 25-08-12 ▲0% $5,000 −$19.01M '25 Q3 25-11-06 LATEST ▲420% $26,000 −$27.36M '25 Q4 26-03-05
Conference
Investor event
2026-09-10
Altimmune, Inc. (ALT) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Confident tone AUD Phase 2 RECLAIM data MASH Phase 3 PERFORMA trial initiation ALD / RESTORE trial
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
Altimmune, Inc. (ALT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
Altimmune, Inc. (ALT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Confident tone Pemvidutide / MASH (PERFORMA Phase III) lead program Liver biopsy / diagnostic approaches in Phase III Phase II IMPACT 48-week data and EASL presentation
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Confident tone PEMB Phase III NASH program planning and FDA engagement Phase II ALD trial enrollment Phase II AUD trial readout timing
Revenue
$26,000*
▲ 420% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
Confident tone MASH / IMPACT trial and pemvidutide efficacy FDA end-of-Phase II meeting and Phase III preparation Alcohol use disorder (AUD) / RECLAIM trial
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript
Confident tone Pipeline expansion - AUD and ALD Phase III planning and FDA interactions NASH / IMPACT Phase II results
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript
Confident tone IMPACT Phase 2b MASH/NASH readout Pemvidutide liver fat and weight loss profile Phase 3 NASH planning and FDA interactions
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Confident tone IMPACT Phase 2b MASH readout Phase 3 and regulatory planning Pipeline expansion to additional indications
Revenue
$5,000*
▼ 86.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
Confident tone Additional Indications Expansion MASH / IMPACT Phase 2b Trial Obesity / Phase 3 Velocity Program
Revenue
$5,000
▼ 98.6% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Altimmune, Inc. (ALT) Q2 2024 Earnings Call
Revenue
$5,000
▼ 16.7% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Altimmune, Inc. (ALT) Q1 2024 Earnings Call Transcript
Confident tone Pemvidutide obesity program and MOMENTUM data MASH / IMPACT Phase 2b trial Partnering strategy for pemvidutide
Revenue
$5,000
▼ 76.2% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Altimmune, Inc. (ALT) Q4 2023 Earnings Call Transcript
Confident tone MOMENTUM Phase II obesity trial results IMPACT Phase IIb MASH trial Body composition and lean mass preservation
Revenue
$37,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Altimmune, Inc. (ALT) Q3 2023 Earnings Call Transcript
Revenue
$362,000
▲ 18000% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Altimmune, Inc. (ALT) Q2 2023 Earnings Call Transcript
Revenue
$6,000
▼ 25% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Altimmune, Inc. (ALT) Q1 2023 Earnings Call Transcript
Revenue
$21,000
▼ 34.4% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Altimmune, Inc. (ALT) Q4 2022 Earnings Call Transcript
Revenue
$*
▼ 103.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Altimmune, Inc. (ALT) Q3 2022 Earnings Call Transcript
Revenue
$2,000
▼ 98.7% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Altimmune, Inc. (ALT) Q2 2022 Earnings Call Transcript
Revenue
$8,000
▼ 94.2% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Altimmune, Inc. (ALT) Q1 2022 Earnings Call Transcript
Revenue
$32,000
▼ 96.2% YoY
Diluted EPS
$-0.44
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Altimmune, Inc. (ALT) Q4 2021 Earnings Call Transcript
Revenue
$3.28M*
▲ 41.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Altimmune, Inc. (ALT) Q3 2021 Earnings Call Transcript
Revenue
$158,000
▼ 94.6% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Altimmune, Inc. (ALT) Q2 2021 Earnings Call Transcript
Revenue
$137,000
▼ 81% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Altimmune, Inc. (ALT) Q1 2021 Earnings Call Transcript
Revenue
$838,000
▼ 62.1% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Altimmune, Inc. (ALT) Q4 2020 Earnings Call Transcript
Revenue
$2.31M*
▲ 301.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Altimmune, Inc. (ALT) Q3 2020 Earnings Call Transcript
Revenue
$2.94M
▲ 356.2% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-16
Altimmune, Inc. (ALT) Q2 2020 Earnings Call Transcript
Revenue
$721,636
▼ 55.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
Altimmune, Inc. (ALT) Q1 2020 Earnings Call Transcript
Revenue
$2.21M
▼ 25.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Altimmune, Inc. (ALT) Q4 2019 Earnings Call
Revenue
$575,802*
▼ 77.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 webcasts
Key facts CIK 1326190 CUSIP 02155H200 13F (30d) 5 filings 5 filers Visit website Investor relations